Abstract
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin’s activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
All Keywords
【초록키워드】 COVID-19, Ivermectin, coronavirus disease, viruses, SARS-CoV-2, coronavirus, antiviral activity, severe acute respiratory syndrome Coronavirus, antiparasitic, Nanotechnology, Coronavirus disease-19, RNA viruses, respiratory, in vivo, patients, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, while, nanotechnologies, DNA and RNA, demonstrated, 【제목키워드】 COVID-19, antiviral activity, expected,
【초록키워드】 COVID-19, Ivermectin, coronavirus disease, viruses, SARS-CoV-2, coronavirus, antiviral activity, severe acute respiratory syndrome Coronavirus, antiparasitic, Nanotechnology, Coronavirus disease-19, RNA viruses, respiratory, in vivo, patients, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, while, nanotechnologies, DNA and RNA, demonstrated, 【제목키워드】 COVID-19, antiviral activity, expected,
{{{ 추상적인 }}}
이버멕틴은 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)를 비롯한 다수의 DNA 및 RNA 바이러스에 대해 항바이러스 활성이 입증된 FDA 승인을 받은 광범위한 항기생충제입니다. 이러한 약속에도 불구하고 이버멕틴의 항바이러스 활성은 생체 내에서 일관되게 입증되지 않았습니다. SARS-CoV-2에 대한 이버멕틴의 활성은 현재 환자에서 조사 중이지만 제형 문제에 대해서는 충분히 강조되지 않았습니다. 여기에서 우리는 코로나바이러스감염증-19(COVID-19)의 맥락에서 이버멕틴의 사용을 둘러싼 문제와 마이크로 및 나노기술을 사용하는 새로운 제형이 이러한 문제를 해결할 수 있는 방법에 대해 논의합니다.